Shrinkage of Thyroid Volume in Sunitinib-Treated Patients with Renal-Cell Carcinoma: A Potential Marker of Irreversible Thyroid Dysfunction?

Background: The multitargeted tyrosine kinase inhibitor sunitinib is known to induce thyroid dysfunction in a substantial proportion of patients treated for advanced renal-cell carcinoma or gastrointestinal stromal tumors. Although sunitinib-induced hypothyroidism seems to be reversible in the majority of patients, some patients develop irreversible thyroid damage resulting in long-lasting thyroid hormone replacement therapy.

Publication year:2010

BOF-keylabel:yes

IOF-keylabel:yes

BOF-publication weight:2

CSS-citation score:1

Authors from:Higher Education